CR11666A - Farmacoforos duales- antagonistas muscarinicos pdea - Google Patents

Farmacoforos duales- antagonistas muscarinicos pdea

Info

Publication number
CR11666A
CR11666A CR11666A CR11666A CR11666A CR 11666 A CR11666 A CR 11666A CR 11666 A CR11666 A CR 11666A CR 11666 A CR11666 A CR 11666A CR 11666 A CR11666 A CR 11666A
Authority
CR
Costa Rica
Prior art keywords
pharmacophors
pdea
dual
muscarinic antagonists
rhinitis
Prior art date
Application number
CR11666A
Other languages
English (en)
Inventor
Francis Callahan James
Lin Guoliang
Wan Zehong
Yan Hongxing
Original Assignee
Glaxo Group Ltd
Total Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Total Sa filed Critical Glaxo Group Ltd
Publication of CR11666A publication Critical patent/CR11666A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de Fórmula (I) y a su uso en el tratamiento de enfermedades respiratorias, incluyendo enfermedades anti-inflamatorias y alérgicas tales como enfermedad pulmonar obstructiva crónica (COPD), asma, rinitis (por ejemplo, rinitis alérgica), dermatitis atópica o psoriasis.
CR11666A 2008-02-06 2010-09-01 Farmacoforos duales- antagonistas muscarinicos pdea CR11666A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2656808P 2008-02-06 2008-02-06

Publications (1)

Publication Number Publication Date
CR11666A true CR11666A (es) 2011-04-28

Family

ID=40935341

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11666A CR11666A (es) 2008-02-06 2010-09-01 Farmacoforos duales- antagonistas muscarinicos pdea

Country Status (19)

Country Link
US (1) US8071588B2 (es)
EP (1) EP2247184A4 (es)
JP (1) JP2011511083A (es)
KR (1) KR20100125295A (es)
CN (1) CN101983009A (es)
AR (1) AR070563A1 (es)
AU (1) AU2009212409A1 (es)
BR (1) BRPI0907519A2 (es)
CA (1) CA2714418A1 (es)
CL (1) CL2009000249A1 (es)
CR (1) CR11666A (es)
DO (1) DOP2010000239A (es)
EA (1) EA201070917A1 (es)
IL (1) IL207346A0 (es)
MX (1) MX2010008685A (es)
PE (1) PE20091563A1 (es)
TW (1) TW200946525A (es)
UY (1) UY31636A1 (es)
WO (1) WO2009100167A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
EP3072943B1 (en) 2015-03-26 2018-05-02 Idemitsu Kosan Co., Ltd. Dibenzofuran/carbazole-substituted benzonitriles
CA2986083A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787249A (fr) 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US3925388A (en) 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
US3856799A (en) 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
US3833594A (en) 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
CA1003419A (en) 1971-11-23 1977-01-11 Theodor Denzel Process for the production of pyrazolo (3,4-b) pyridines
US3840546A (en) 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3979399A (en) 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US4364948A (en) 1981-09-28 1982-12-21 Ici Americas Inc. Pyrazolo[3,4-b]pyridine compounds
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6670364B2 (en) 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
US6677365B2 (en) 2001-04-03 2004-01-13 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
WO2003032989A1 (en) 2001-10-18 2003-04-24 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
US7544675B2 (en) 2002-04-18 2009-06-09 Ucb, S.A. Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
MXPA05002887A (es) 2002-09-16 2005-05-27 Glaxo Group Ltd Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de fosfodiesterasa.
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
WO2004091482A2 (en) 2003-04-07 2004-10-28 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
TW200519109A (en) 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
UY28417A1 (es) 2003-07-17 2005-02-28 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
PE20050250A1 (es) 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
DE602004030930D1 (de) 2003-10-14 2011-02-17 Glaxo Group Ltd Muscarinische acetylcholin-rezeptor-antagonisten
OA13270A (en) 2003-10-17 2007-01-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists.
TW200524577A (en) 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
AR046784A1 (es) 2003-12-03 2005-12-21 Glaxo Group Ltd Compuesto de amina ciclica composicion farmaceutica que lo comprende y su uso para preparar esta ultima
TW200530226A (en) 2003-12-03 2005-09-16 Glaxo Group Ltd Novel M3 muscarinic acetylcholine receptor antagonists
WO2005058892A1 (en) 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1751089A4 (en) 2004-03-11 2010-03-10 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
US20090253908A1 (en) 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
AU2005223351A1 (en) 2004-03-16 2005-09-29 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
EP1725241A4 (en) 2004-03-17 2009-03-25 Glaxo Group Ltd ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC M3 RECEPTOR
WO2005094834A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
JP2007529511A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US7384946B2 (en) 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2005099706A2 (en) 2004-04-07 2005-10-27 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
US7598267B2 (en) 2004-05-13 2009-10-06 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
PE20060367A1 (es) 2004-05-28 2006-04-28 Glaxo Group Ltd Compuestos 8-azoniabiciclo[3.2.1]octanos como antagonistas del receptor de acetilcolina muscarinico
US20080287487A1 (en) 2004-06-30 2008-11-20 Anthony William James Cooper Muscarinic Acetylcholine Receptor Antagonists
US20070293531A1 (en) 2004-08-05 2007-12-20 Jakob Busch-Petersen Muscarinic Acetycholine Receptor Antagonists
JP2008509158A (ja) 2004-08-06 2008-03-27 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
US20090258858A1 (en) 2004-10-29 2009-10-15 Jakob Busch-Petersen Muscarinic acetylcholine receptor antagonists
WO2006055553A2 (en) * 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
US20090142279A1 (en) 2004-11-15 2009-06-04 Budzik Brian W Novel m3 muscarinic acetylcholine receptor antagonists
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
WO2007016650A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
JP2009503099A (ja) 2005-08-02 2009-01-29 グラクソ グループ リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1937068A4 (en) 2005-08-18 2010-08-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
WO2007123953A2 (en) 2006-04-19 2007-11-01 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
GB0614570D0 (en) * 2006-07-21 2006-08-30 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
DOP2010000239A (es) 2011-03-31
EP2247184A4 (en) 2012-07-18
EA201070917A1 (ru) 2011-02-28
CA2714418A1 (en) 2009-08-13
PE20091563A1 (es) 2009-11-05
TW200946525A (en) 2009-11-16
EP2247184A1 (en) 2010-11-10
CL2009000249A1 (es) 2009-09-11
IL207346A0 (en) 2010-12-30
UY31636A1 (es) 2009-08-03
US20090203677A1 (en) 2009-08-13
JP2011511083A (ja) 2011-04-07
AR070563A1 (es) 2010-04-21
KR20100125295A (ko) 2010-11-30
US8071588B2 (en) 2011-12-06
AU2009212409A1 (en) 2009-08-13
BRPI0907519A2 (pt) 2015-07-28
CN101983009A (zh) 2011-03-02
MX2010008685A (es) 2010-08-30
WO2009100167A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
PA8774101A1 (es) Compuesto de pirmidina
CL2008000307A1 (es) Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc.
MX2012006964A (es) Nuevos antagonistas del receptor ccr2 y usos de los mismos.
ECSP11011163A (es) Pirimidin-4-carboxamidas cíclicas en calidad de antagonistas del receptor CCR2 para el tratamiento de inflamación, asma y EPOC
CR9832A (es) Compuestos de pirimidina amida como inhibidores de pgds
CL2008001593A1 (es) Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma.
CL2007002163A1 (es) Compuestos derivados de 2-fenilindol, antagonistas del receptor de prostaglandina d2; composicion farmaceutica; y uso para tratar enfermedades alergicas tales como asma bronquial y rinitis alergica, broncoconstriccion, epoc, accidente cerebrovascular
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
CL2016002888A1 (es) Compuestos derivados de pirazolopiridinas y pirazolopirimidinas; composicion farmacéutica y su uso como inhibidores selectivos de janus quinasas (jak) en el tratamiento de enfermedades como congestion nasal, asma, epoc, rinitis alergica, diabetes entre otras.
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
BR112015015468B8 (pt) Composto, e, composição farmacêutica
ATE538100T1 (de) Aminotetrahydroindazoloessigsäuren
CL2007002159A1 (es) Uso de compuestos derivados de quinuclidina para tratar enfermedades tales como asma, enfermedad obstructiva cronica, bronquitis cronica, tos y enfisema; compuestos derivados de quinuclidina; composicion farmaceutica que comprende a dichos compuestos.
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
CL2009000198A1 (es) Compuestos derivados del acido {2'-[(amino n,n-disustituido)-metil]-bifenil-3-il} acetico, mediadores de prostaglandina d2; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad respiratoria, alergica o inflamatoria, tal como el asma, epoc o rinitis alergica.
CL2011002461A1 (es) Compuestos derivados de tipo amida de compuestos [3,2-c] pirazol con actividad glucocorticoide utiles en condiciones inflamatorias y alergicas como asma, epoc o rinitis alergica.
UY31687A1 (es) Nueva dosificacion y formulacion
ECSP11011082A (es) Compuestos, composición farmaceutica y métodos para utilizarse en el tratamiento de desórdenes metabólicos
BR112012007635A2 (pt) derivados de feniloxadiazol como inibidores de pgds
HN2010002403A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
CR11666A (es) Farmacoforos duales- antagonistas muscarinicos pdea
CL2009000876A1 (es) Forma cristalina maleato de orvepitant anhidro; composicion farmaceutica; y su uso para tratar trastornos del sistema nervioso central, tales como depresion, ansiedad, trastornos de estres postraumatico, emesis y/o trastornos del sueno.
UY31635A1 (es) Farmacóforos duales-antagonistas muscarínicos de pde4
CL2011002618A1 (es) Compuestos derivados de arilsulfonamidas 2,5-disustituidas; composición farmacéutica que los comprende; y uso del compuesto o de la composición como moduladores de ccr3 para prevenir o tratar una enfermedad inflamatoria tal como asma, asma inducido por ejercicio, rinitis alérgica, dermatitis atópica, conjuntivitis alérgica o enfermedad obstructiva crónica.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)